10-Q: ImmunityBio Reports Q1 2024 Results, ANKTIVA Approved by FDA

ImmunityBio's Q1 2024 results show a net loss of $134.1 million, but the company achieved a significant milestone with FDA approval of ANKTIVA.

Summary

• ImmunityBio reported a net loss of $134.1 million for the first quarter of 2024, compared to a net loss of $116.3 million in the same period last year.
• The company's revenue was $40,000, a significant decrease from $360,000 in Q1 2023.
• Research and development expenses decreased to $53.4 million from $79.3 million year-over-year, while selling, general, and administrative expenses increased to $41.9 million from $32.7 million.
• The company's cash and cash equivalents, and marketable securities totaled $170.5 million as of March 31, 2024, down from $267.4 million at the end of 2023.
• A major highlight was the FDA approval of ANKTIVA on April 22, 2024, which is expected to drive future revenue.
• The company has requested a $100 million second payment from Oberland following the FDA approval of ANKTIVA.
• The company had $208.8 million available for future stock issuances under the ATM as of March 31, 2024, which was increased to $300.8 million in April 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the FDA approval of ANKTIVA is a major positive, the company's financial performance in Q1 2024 was worse than the same period last year, and there are significant risks and uncertainties related to its future operations and financial position. The company's reliance on external funding and the potential for dilution are also concerning.

Positives

• FDA approval of ANKTIVA is a significant milestone and is expected to drive future revenue.
• The company has secured a collaboration with SII for BCG manufacturing, addressing potential supply issues.
• The company has a positive overall survival results of ANKTIVA combined with checkpoint inhibitors in NSCLC.
• The company has a meeting scheduled with the FDA in June 2024 to discuss a path to a registration filing of ANKTIVA plus checkpoint inhibitors in secondand third-line NSCLC patients.
• The company has increased the amount available under the ATM to $300.8 million.

Negatives

• The company reported a net loss of $134.1 million for Q1 2024, an increase from $116.3 million in Q1 2023.
• Revenue decreased significantly to $40,000 from $360,000 year-over-year.
• The company's cash and cash equivalents, and marketable securities decreased from $267.4 million at the end of 2023 to $170.5 million as of March 31, 2024.
• The company has a substantial amount of debt and revenue interest liability.
• The company has a history of operating losses and may never be profitable.

Risks

• The company's ability to commercialize ANKTIVA successfully is uncertain.
• The company is dependent on third-party manufacturers and CMOs, which could lead to supply chain issues.
• The company may not be able to obtain regulatory approval for its other product candidates.
• The company may not be able to secure additional financing on favorable terms.
• The company is subject to various legal proceedings and claims.
• The company is subject to risks related to intellectual property protection and infringement.
• The company is subject to risks related to healthcare and other government regulations.
• The company is subject to risks related to the volatility of its common stock and the potential for dilution.
• The company is subject to risks related to the control of the company by Dr. Soon-Shiong.
• The company is subject to risks related to the ongoing COVID-19 pandemic.

Future Outlook

The company expects to begin generating revenue from ANKTIVA sales, but it will take time to establish significant revenue. The company also plans to continue investing in research and development activities and may seek additional financing.

Management Comments

• Based on ANKTIVAs unique mechanism of action, we believe it has the potential to play a key role as a backbone for immunotherapy beyond T cells alone across multiple tumor types in the years to come.
• We plan to begin commercial distribution of our approved product as early as May 2024.
• We plan to conduct clinical trials to study iBCG and sBCG manufactured by SII in combination with ANKTIVA for the treatment of different types of bladder and other cancers.

Industry Context

The approval of ANKTIVA and the collaboration with SII are significant developments in the immunotherapy space, particularly for bladder cancer treatment. The company is positioning itself to address the limitations of current treatments and reduce the need for high-dose chemotherapy.

Comparison to Industry Standards

• The company's Q1 2024 net loss of $134.1 million is higher than the $116.3 million loss in Q1 2023, indicating a worsening financial position compared to its own past performance.
• Compared to other biotechnology companies in the clinical stage, ImmunityBio's revenue is minimal, highlighting its reliance on future product sales.
• The company's cash burn rate is high, with cash and cash equivalents decreasing from $267.4 million to $170.5 million in one quarter, which is a concern compared to industry benchmarks.
• The FDA approval of ANKTIVA is a significant achievement, placing ImmunityBio in a position to compete with companies like Merck, which currently dominates the BCG market.
• The collaboration with SII for BCG manufacturing is a strategic move to address supply chain issues, which is a common challenge in the biopharmaceutical industry.
• The positive overall survival results of ANKTIVA combined with checkpoint inhibitors in NSCLC is a promising development, potentially positioning ImmunityBio to compete with companies like Bristol Myers Squibb and Merck in the NSCLC market.

Legal Proceedings

• The company is involved in an arbitration with Shenzhen Beike Biotechnology Co. Ltd. related to a license agreement.
• The company is subject to a securities class action lawsuit related to the disclosure of an FDA CRL.
• The company is involved in an arbitration with Dr. Hing Wong and HCW Biologics, Inc. related to breach of contract and misappropriation of trade secrets.

Related Party Transactions

• The company has significant related-party debt with entities affiliated with Dr. Soon-Shiong.
• The company has entered into multiple agreements with the Clinic, a related party, to conduct clinical trials.
• The company has a shared services agreement with NantWorks, a related party, for corporate, general and administrative, and research and development support services.
• The company has various lease agreements with related parties for office and manufacturing space.

Stakeholder Impact

• Shareholders face the risk of dilution from potential equity offerings and conversion of debt.
• Employees may be affected by changes in the company's financial position and strategic direction.
• Customers (patients and healthcare providers) will benefit from the availability of ANKTIVA, but may face challenges related to access and reimbursement.
• Suppliers and creditors may be affected by the company's financial performance and ability to meet its obligations.

Next Steps

• The company plans to begin commercial distribution of ANKTIVA as early as May 2024.
• The company will continue to invest in research and development activities.
• The company will continue to seek regulatory approvals for its other product candidates.
• The company will continue to explore potential global strategic partnership transactions for commercialization of ANKTIVA for certain indications.
• The company will continue to conduct clinical trials to study iBCG and sBCG manufactured by SII in combination with ANKTIVA for the treatment of different types of bladder and other cancers.

Key Dates

Keywords

ANKTIVA, FDA approval, NMIBC, BCG, immunotherapy, clinical trials, biotechnology, cancer, revenue, net loss, financial results, pharmaceutical, drug development, stock offering, warrants, promissory notes, RIPA, Oberland, SII, NSCLC